DE69435083D1 - Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen - Google Patents

Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen

Info

Publication number
DE69435083D1
DE69435083D1 DE69435083T DE69435083T DE69435083D1 DE 69435083 D1 DE69435083 D1 DE 69435083D1 DE 69435083 T DE69435083 T DE 69435083T DE 69435083 T DE69435083 T DE 69435083T DE 69435083 D1 DE69435083 D1 DE 69435083D1
Authority
DE
Germany
Prior art keywords
receptor
antibodies
therapeutic uses
inhibitors
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435083T
Other languages
English (en)
Other versions
DE69435083T2 (de
Inventor
Patricia A Tekamp-Olson
Guy Mullenbach
Mary Ellen Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE69435083D1 publication Critical patent/DE69435083D1/de
Application granted granted Critical
Publication of DE69435083T2 publication Critical patent/DE69435083T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69435083T 1993-09-14 1994-09-13 Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen Expired - Lifetime DE69435083T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/121,105 US6448379B1 (en) 1993-09-14 1993-09-14 IL8 inhibitors
US121105 1993-09-14

Publications (2)

Publication Number Publication Date
DE69435083D1 true DE69435083D1 (de) 2008-04-17
DE69435083T2 DE69435083T2 (de) 2009-03-12

Family

ID=22394586

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435083T Expired - Lifetime DE69435083T2 (de) 1993-09-14 1994-09-13 Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen
DE69431843T Expired - Lifetime DE69431843T2 (de) 1993-09-14 1994-09-13 Il-8 inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69431843T Expired - Lifetime DE69431843T2 (de) 1993-09-14 1994-09-13 Il-8 inhibitoren

Country Status (11)

Country Link
US (2) US6448379B1 (de)
EP (3) EP0719285B1 (de)
JP (3) JPH09502725A (de)
AT (2) ATE229036T1 (de)
AU (1) AU697190B2 (de)
CA (1) CA2171289C (de)
DE (2) DE69435083T2 (de)
DK (1) DK1283217T3 (de)
ES (1) ES2302774T3 (de)
PT (1) PT1283217E (de)
WO (1) WO1995007934A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000893A1 (en) * 1995-06-20 1997-01-09 Chiron Corporation Interleukin-8 receptor binding compounds
AU777766B2 (en) * 1996-07-05 2004-10-28 Cancer Research Technology Limited Inhibitors of the interaction between p53 and MDM2
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0939634A4 (de) * 1996-08-15 2001-02-21 Smithkline Beecham Corp Il-8 rezeptor antagonisten
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
ES2156534B1 (es) * 1999-02-03 2002-02-01 Smithkline Beecham Sa Nuevos inhibidores de la interaccion entre la interleuquina-8 y sus receptores
JP2003530325A (ja) * 2000-03-31 2003-10-14 イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
CA3037071A1 (en) * 2016-10-03 2018-04-12 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
EP3737696A1 (de) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Kombinationstherapie mit anti-il-8-antikörpern und anti-pd-1-antikörpern zur behandlung von krebs
JP7429427B2 (ja) 2020-01-31 2024-02-08 株式会社大都技研 抽出装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
JP2866182B2 (ja) 1990-10-08 1999-03-08 日本ケミファ株式会社 エンドセリン受容体
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5783415A (en) * 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
JPH06506596A (ja) * 1991-04-10 1994-07-28 ザ　トラスティーズ　オブ　ボストン　ユニバーシティー インターロイキン−８受容体及び関連分子及び方法
US5374506A (en) 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor

Also Published As

Publication number Publication date
AU697190B2 (en) 1998-10-01
DK1283217T3 (da) 2008-07-07
US6436390B1 (en) 2002-08-20
EP1932856A3 (de) 2009-09-30
WO1995007934A2 (en) 1995-03-23
ES2302774T3 (es) 2008-08-01
DE69431843T2 (de) 2003-07-10
JP4122321B2 (ja) 2008-07-23
EP1932856A2 (de) 2008-06-18
DE69431843D1 (de) 2003-01-23
ATE229036T1 (de) 2002-12-15
EP0719285B1 (de) 2002-12-04
CA2171289C (en) 2007-04-10
JP2008169227A (ja) 2008-07-24
DE69435083T2 (de) 2009-03-12
US6448379B1 (en) 2002-09-10
CA2171289A1 (en) 1995-03-23
AU7834894A (en) 1995-04-03
JP2005023085A (ja) 2005-01-27
JPH09502725A (ja) 1997-03-18
EP1283217B1 (de) 2008-03-05
ATE388168T1 (de) 2008-03-15
EP0719285A1 (de) 1996-07-03
EP1283217A3 (de) 2003-09-17
WO1995007934A3 (en) 1995-04-13
EP1283217A2 (de) 2003-02-12
PT1283217E (pt) 2008-06-11

Similar Documents

Publication Publication Date Title
DE69435083D1 (de) Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen
DE69839270D1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
ATE359090T1 (de) Monoklonale antikörper spezifisch gegen vegf- rezeptoren und ihre verwendung
DE69334158D1 (de) Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
BR0315123A (pt) Composições farmacêuticas direcionadas a receptores erb-b1
NO20003550L (no) Farmasøytiske sammensetninger og anvendelse herav
ATE247667T1 (de) Gdnf-rezeptor und dessen verwendung
DK0851920T3 (da) Varianter af vaskulær endotelcellevækstfaktor, anvendelser af disse samt fremgangsmåder til fremstilling deraf
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
DE60034586D1 (de) April rezeptor (bcma) und verwendungen davon
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE60128452D1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
ATE312915T1 (de) Neurturin-rezeptor
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
AR002996A1 (es) Isoxazolinas mejoradas antagonistas del receptore de fibrinogeno.
MXPA02008462A (es) Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis.
DE59611293D1 (de) Protein mit dnase-aktivität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition